Nanomedicines for Cancer Therapy: State-of-the-art and Limitations to Pre-clinical Studies That Hinder Future Developments

Overview

Journal Front Chem

Specialty Chemistry

Date 2014 Sep 10

PMID 25202689

Citations 45

Authors

Charlene M Dawidczyk

Luisa M Russell

Peter C Searson

Affiliations

Soon will be listed here.

Abstract

The ability to efficiently deliver a drug or gene to a tumor site is dependent on a wide range of factors including circulation time, interactions with the mononuclear phagocyte system, extravasation from circulation at the tumor site, targeting strategy, release from the delivery vehicle, and uptake in cancer cells. Nanotechnology provides the possibility of creating delivery systems where the design constraints are decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing tumor accumulation, and improving efficacy. The physico-chemical properties of nanoparticle-based delivery platforms introduce additional complexity associated with pharmacokinetics, tumor accumulation, and biodistribution. To assess the impact of nanoparticle-based delivery systems, we first review the design strategies and pharmacokinetics of FDA-approved nanomedicines. Next we review nanomedicines under development, summarizing the range of nanoparticle platforms, strategies for targeting, and pharmacokinetics. We show how the lack of uniformity in preclinical trials prevents systematic comparison and hence limits advances in the field.

Citing Articles

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer.

Hoshi R, Gorospe K, Labouta H, Azad T, Lee W, Thu K Pharmaceutics. 2024; 16(9).

PMID: 39339217 PMC: 11434872. DOI: 10.3390/pharmaceutics16091181.

Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.

Ashoub M, Razavi R, Heydaryan K, Salavati-Niasari M, Amiri M Eur J Med Res. 2024; 29(1):224.

PMID: 38594732 PMC: 11003188. DOI: 10.1186/s40001-024-01822-7.

Applications of Nanomedicine in Brain Tumor Therapy: Nanocarrierbased Drug Delivery Platforms, Challenges, and Perspectives.

Verma R, Rao L, Kumar H, Bansal N, Deep A, Parashar J Recent Pat Nanotechnol. 2023; 19(1):99-119.

PMID: 37937554 DOI: 10.2174/0118722105244482231017102857.

A di-electrophoretic simulation procedure of iron-oxide micro-particle drug attachment system for leukemia treatment using COMSOL software: a potential treatment reference for LMICs.

Kiwumulo H, Muwonge H, Ibingira C, Lubwama M, Kirabira J, Ssekitoleko R Front Med Technol. 2023; 5:1250964.

PMID: 37901748 PMC: 10602814. DOI: 10.3389/fmedt.2023.1250964.

Emetic Tartar-Loaded Liposomes as a New Strategy for Leishmaniasis Treatment.

Coelho L, Souza M, Cassali G, Silva R, Paiva M, Barros A Pharmaceutics. 2023; 15(3).

PMID: 36986765 PMC: 10056186. DOI: 10.3390/pharmaceutics15030904.

References

Yu B, Mao Y, Bai L, Herman S, Wang X, Ramanunni A . Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood. 2012; 121(1):136-47. PMC: 3538326. DOI: 10.1182/blood-2012-01-407742. View

Benezra M, Penate-Medina O, Zanzonico P, Schaer D, Ow H, Burns A . Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011; 121(7):2768-80. PMC: 3223837. DOI: 10.1172/JCI45600. View

Michalet X, Pinaud F, Bentolila L, Tsay J, Doose S, Li J . Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005; 307(5709):538-44. PMC: 1201471. DOI: 10.1126/science.1104274. View

Ruoslahti E . RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996; 12:697-715. DOI: 10.1146/annurev.cellbio.12.1.697. View

Helbok A, Rangger C, von Guggenberg E, Saba-Lepek M, Radolf T, Thurner G . Targeting properties of peptide-modified radiolabeled liposomal nanoparticles. Nanomedicine. 2011; 8(1):112-8. DOI: 10.1016/j.nano.2011.04.012. View

Morales-Avila E, Ferro-Flores G, Ocampo-Garcia B, De Leon-Rodriguez L, Santos-Cuevas C, Garcia-Becerra R . Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression. Bioconjug Chem. 2011; 22(5):913-22. DOI: 10.1021/bc100551s. View

Gabizon A, Shmeeda H, Barenholz Y . Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42(5):419-36. DOI: 10.2165/00003088-200342050-00002. View

Yang K, Hu L, Ma X, Ye S, Cheng L, Shi X . Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv Mater. 2012; 24(14):1868-72. DOI: 10.1002/adma.201104964. View

Shi S, Yang K, Hong H, Valdovinos H, Nayak T, Zhang Y . Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials. 2013; 34(12):3002-9. PMC: 3570619. DOI: 10.1016/j.biomaterials.2013.01.047. View

10.

Cornelissen B, Able S, Kersemans V, Waghorn P, Myhra S, Jurkshat K . Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. Biomaterials. 2012; 34(4):1146-54. DOI: 10.1016/j.biomaterials.2012.10.054. View

11.

Sailor M, Park J . Hybrid nanoparticles for detection and treatment of cancer. Adv Mater. 2012; 24(28):3779-802. PMC: 3517011. DOI: 10.1002/adma.201200653. View

12.

Lu W, Zhang G, Zhang R, Flores 2nd L, Huang Q, Gelovani J . Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 2010; 70(8):3177-88. PMC: 2856125. DOI: 10.1158/0008-5472.CAN-09-3379. View

13.

Prato M, Kostarelos K, Bianco A . Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res. 2007; 41(1):60-8. DOI: 10.1021/ar700089b. View

14.

Furger K, Allan A, Wilson S, Hota C, Vantyghem S, Postenka C . Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res. 2003; 1(11):810-9. View

15.

Niemeyer C . Nanoparticles, Proteins, and Nucleic Acids: Biotechnology Meets Materials Science. Angew Chem Int Ed Engl. 2018; 40(22):4128-4158. DOI: 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S. View

16.

Daniels T, Bernabeu E, Rodriguez J, Patel S, Kozman M, Chiappetta D . The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2011; 1820(3):291-317. PMC: 3500658. DOI: 10.1016/j.bbagen.2011.07.016. View

17.

Kamen B, Smith A . A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev. 2004; 56(8):1085-97. DOI: 10.1016/j.addr.2004.01.002. View

18.

Choi C, Alabi C, Webster P, Davis M . Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010; 107(3):1235-40. PMC: 2824286. DOI: 10.1073/pnas.0914140107. View

19.

Hoang B, Lee H, Reilly R, Allen C . Noninvasive monitoring of the fate of 111In-labeled block copolymer micelles by high resolution and high sensitivity microSPECT/CT imaging. Mol Pharm. 2009; 6(2):581-92. DOI: 10.1021/mp8002418. View

20.

Hong H, Yang K, Zhang Y, Engle J, Feng L, Yang Y . In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano. 2012; 6(3):2361-70. PMC: 3314116. DOI: 10.1021/nn204625e. View